Dance Biopharm Names Lee to Board of Directors
15 May 2019 - - US-based clinical stage biopharma company Dance Biopharm Holdings, Inc has appointed Kenneth B. Lee, Jr. to its board of directors, the company said.

He will also serve as the chair of the audit committee of the board.

Lee has more than 40 years of experience in advising biotechnology companies in all aspects of a company's financial life cycle from strategic fundraising to initial public offering and mergers and acquisitions.

Kenneth Lee currently serves as a General Partner with Hatteras Venture Partners, a venture fund focused on healthcare and life sciences, which he joined in 2003, and where he is involved in deal sourcing, investment decisions and implementing exit strategies.

Previously, he was president of A.M. Pappas and Associates, LLC, a venture development firm, which he joined following 29 years with Ernst and Young. At Ernst and Young, Kenneth co-founded the firm's national life sciences practice.

Lee is a nationally-recognized financial matters expert and has served on eight public life sciences company boards, including Abgenix, CV Therapeutics, Maxygen and OSI Pharmaceuticals.

He previously served as chairman of the Inspire Pharmaceuticals board until the company's sale to Merck in 2011.

Ken currently serves on the boards of Aralez, Inc., Eyenovia and BioCryst Pharmaceuticals. He received his B.A. in Business Administration from Lenoir-Rhyne College and his MBA from the University of North Carolina at Chapel Hill.

Dance Biopharm is a private company based in the San Francisco Bay Area focused on developing novel inhaled formulations of biologics to treat diabetes and other serious chronic diseases.

The company began operations in 2010, and was founded by John Patton, Ph.D., who has over 25 years of experience developing numerous inhaled therapies including insulin.